- The generic drug market is seeing significant growth, driven by Indian firms and regional markets, with major players like Aurobindo, J&J, and GSK involved.
- Indian drug makers are targeting the North American market.
- India supplies 40 per cent of generic drugs consumed in the US, with government programs like Medicare procuring these drugs to cut expenditure, though tariff hikes pose a threat.
- Slotkin argues Medicare should negotiate drug prices while criticizing Trump's proposed tariffs on generic drugs.
Tariffs are introducing uncertainty into the drug market structure.
8 reports, 2 independent
Updated Oct 14
Gone quiet
- Reports
- 8
- Developments
- 1
- Repetition
- 88%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tariffs are introducing uncertainty into the drug market structure.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Medicare
US federal health insurance